A diet supplemented with vitamin D can help support healthy weight loss and reduce fat percentage, a new clinical study revealed.
A trial was conducted over a three-month period with 125 overweight and obese Southeastern European Caucasians with vitamin D deficiency or insufficiency.
Participants were prescribed vitamin D3 3000 IU/d oral spray supplementation, or a placebo, alongside a calorie-restricted diet programme of 600 kcal less than
the total energy expenditure of each individual.
The report stated that the group who were prescribed vitamin D witnessed significant improvements in serum 25(OH)D level and a greater reduction in body weight, BMI,
and fat percentage in all individuals within this group.
The study supported by BetterYou found that with the prevalence of low vitamin D becoming a serious global health problem in all ages, even in areas with natural sun
exposure throughout the year, the study shines a light on the importance of vitamin D supplementation.
The Health and Social Care Committee (HSCC) has undertaken an inquiry into prevention and has published its first report of the series which focuses on
vaccination.
It has announced ten workstreams that will form the basis of inquiry, of which vaccination is one.
HSCC said: "The UK has long been one of the world leaders on vaccination - one of the most successful and cost-effective preventative tools available. However,
if challenges around uptake and bureaucratic processes in clinical trial set-up are not addressed, there is a very real risk that the UK's position as a global
leader could be lost. This cannot be allowed to happen and in this report we set out some of the steps that we think will make a difference."
It recommended a more flexible delivery model making use of a wider range of healthcare professionals.
"The NHSE vaccination and immunisation strategy must have a strong focus on tackling practical challenges that limit vaccination access, make best use of a wider
array of professionals, empower local leaders to pursue ways of addressing uptake in their own areas, and to set out guidance and examples of best practice around
how voices other than NHSE can communicate important messaging around vaccination programmes," it suggested.
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door
for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees.
The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on
an ongoing clinical trial involving 4,526 participants.
Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be
used as part of the national vaccination programme.
The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections
in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
Professional translators recreate texts, not simply matching word-for-word, but understanding the underlying meaning, purpose, and interpretation of the original
language, and reproduce it using appropriate terminology and structure to ensure there is no potential for misunderstanding.
An experienced technical translator addresses conventions to ensure the meaning of the information is preserved, using medical expertise and quality review processes
to adapt documentation to meet the needs of patients, medical practitioners, and peers.
Attention to detail is fundamental to medical translations and a non-technical translation is an unacceptably high risk for any organisation involved in publishing
or circulating medical information of any kind.
WHAT IS MEDICAL TRANSLATION?
Medical translation is a technical process where capable translators reproduce content or documentation used anywhere in the medical industry, including psychiatry,
systematic reviews, tuition and training, patient communications for pharmaceutical translation services.
Important clinical trial translations can include labelling, prescriptions, medical devices and patient records, with millions of medicines and treatments used
globally and written in multiple languages.
Qualified medical translators must have exceptional linguistic skills but also a thorough understanding of medical sciences in all the native languages concerned.
However, the complexity of translating one label or one document into several languages can mean that organisations may assume a simple translation is sufficient -
when it is anything but!
Britain has become the first country to approve a Codiv-19 vaccine that targets both the original and Omicron variant of the virus.
Medicines regulator MHRA approved the so-called bivalent vaccine made by US drug company Moderna as a booster for adults.
The agency's decision was based on clinical trial data that showed the booster triggered "a strong immune response" against both Omicron (BA.1) and the original
2020 virus, it said.
The MHRA also cited an exploratory analysis in which the shot was also found to generate a good immune response against the currently dominant Omicron offshoots BA.4
and BA.5.
"The first generation of Covid-19 vaccines being used in the UK continue to provide important protection against the disease and save lives," MHRA chief executive
June Raine said in a statement.
"What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve."
New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a
standalone prescription medicine and vaccine business since carving out its consumer health division Haleon.
After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of
strong results.
The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy.
Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain
around U.S. litigation over heartburn drug Zantac.
Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a second "bivalent" vaccine as a Covid-19 booster.
The updated booster vaccine made by Pfizer/BioNTech, targeting two coronavirus variants, has been approved for use in individuals aged 12 years and above.
In each dose of the booster vaccine, 'Comirnaty bivalent Original/Omicron', half of the vaccine (15 micrograms) targets the original virus strain and the other
half (15 micrograms) targets Omicron (BA.1).
Dr June Raine, MHRA chief executive said: "I am pleased to announce that we now have a second approved vaccine for the UK Autumn booster programme. The clinical
trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain.
Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against Covid-19 variants. We have in place a comprehensive
safety surveillance strategy for all UK-approved Covid-19 vaccines, and this will include the updated booster we approved today."
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Anastrozole in a new use to prevent the disease.
The off-patent drug has been used as a breast cancer treatment for many years.
Clinical trials have shown that it can reduce the incidence of breast cancer in post-menopausal women with increased risk by almost 50 per cent.
Health Minister Will Quince expressed his happiness on the approval of the drug that can help to prevent this "cruel disease".
He said: "We've already seen the positive effect Anastrozole can have in treating the disease when it has been detected in post-menopausal women and now we
can use it to stop it developing at all in some women.
The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel)
which is said to benefit people with triple negative breast cancer.
Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live.
NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer.
Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%.
"This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE.
NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy.
Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple
negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.
The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin.
It's final draft guidance is expected to be available on the July 20.
Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with
controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides.
NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo.
Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.
Governments should invest in vaccines for all strains of influenza virus that exist in the animal kingdom as an insurance policy in case of an outbreak in
humans, the incoming chief scientist at the World Health Organization said on Monday (Feb. 20).
Countries ranging from the United States and Britain to France and Japan have suffered record losses of poultry in outbreaks of avian flu in the past year.
The recent spread to mammals of H5N1 - commonly known as bird flu - needed to be monitored, but the risk to humans remained low, the WHO said earlier this month.
Incoming WHO chief scientist Jeremy Farrar said he would like to see the pharmaceutical industry at least conduct some clinical trials for all influenza strains such
that the world would not have to start from scratch to initiate global manufacturing should the need arise.
"My concern that we're in slow motion watching something which may never happen," he added in a media briefing. "But if it were to happen, would we look back on what
we're doing at the moment and say, why didn't we do more?"
Developing a new medical drug is no small feat. It requires extensive research, knowledge, expertise in the field, rigorous testing and iteration of prototypes,
and strong organizational skills to manage these tasks. It is important to use the right tools to make this process as efficient and successful as possible. With the
right tools available, you can streamline development, manage resources and personnel more effectively, and maximize the chances of success. Here are some tools that
might be useful when developing a new medical drug:
ANALYTICAL TESTING TOOLS
One of the best tools available to medical drug developers is analytical testing tools. These allow you to quickly and accurately test various components of the new
medication, ensuring that it meets all safety requirements and is ready for clinical trials. As highlighted by the team behind Venogen, various methods of analyzing,
chemical identification, and purity certification can be used to ensure product quality. Be sure to select a tool that can accurately analyze the specific components
of your new drug.
When finding analytical testing tools for your drug development process, it is important to consider the tool's scalability. Consider the size and scope of your
project and select a tool that can grow with you. You can also work with experts to find the right analytical testing tools for your development needs.
Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse.
This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat
non-small cell lung cancer (NSCLC).
More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year.
It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy.
Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.
The General Pharmaceutical Council reiterated its stand on Covid-19 vaccination, saying, "Pharmacists and pharmacy technicians working in all settings across Great Britain should be vaccinated against Covid -19, unless they are medically exempt."
In a statement issued today (February 11), it strongly urged all pharmacyprofessionals, students and trainees to get fully vaccinated at the earliest.
This reiteration follows the government's announcement on January 31, 2022 that it would not proceed with Covid vaccination as a mandatory condition of deployment
for health and care staff providing CQC-regulated services in England.
The Council stated that clinical trials have proven the efficacy and safety of Covid vaccines and the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised their use in the UK.
The government on Wednesday (March 2) announced an investment of £260 million to support research, development and manufacturing of new drugs, devices and
diagnostics.
Of the total funding, up to £200m has been allocated for research to better access NHS data through Trusted Research Environments and digital clinical trial services, enabling availability of crucial data with the highest levels of privacy.
This will allow the NHS to deliver new life-saving treatments to patients, tackle health inequalities and improve patient care, a government release stated.
The remaining £60m will support commercial-scale manufacturing investments by companies at the leading-edge of innovation, from cell and gene therapies and earlier
and better diagnostic technologies, to medical devices.
The funding for manufacturing investments will be distributed through the new Life Sciences Innovative Manufacturing Fund (LSIMF), following the success of the earlier Medicines and Diagnostics Manufacturing Transformation Fund.
As the weather gets colder, we're all looking for ways to get through the winter months. One of the most popular natural remedies is ginger. It's been used for thousands of years and has been shown to relieve symptoms like sore throat and coughing as well as boost overall health. People often use ginger as a home remedy for treating colds and sore throats due to its antibacterial markers that can help handle pain and inflammation. The Ginger (Zingiber officinale) root is a perennial plant. Our forefathers have consumed ginger as a herbal therapy for decades after decades to cure many health conditions, from arthritis to abdominal pain. Today, we often use ginger when we have a cough or cold. The scientific database reveals that ginger has medicinal effects that could ease the symptoms of a cold or sore throat.
This article will examine how ginger may help colds and how you can use it in teas, juices, and other home remedies.
How is ginger good for treating Colds?
There is no definitive proof that ginger can cure or eliminate colds from roots, but research indicates that it may help control them. Ginger can also aid in improving cold symptoms.
One study review shows that there is evidence that ginger can help:
prevent colds
control or relieve a sore throat
ease congestion
decrease inflammation
However, researchers need to examine ginger's additional benefits to support this evidence.
Medicinal properties
Ginger has blends called gingerols and shogaols. Experimenters consider that these compounds give ginger its therapeutic properties. It is a potent anti-inflammatory. It's also a natural expectorant and decongestant, which helps to clear up congestion. Ginger is high in vitamin C and manganese, both essential nutrients for boosting your immune system during the cold season. While ginger may not be a cure-all for the common cold or flu (it's always best to consult your doctor if you're sick), it can help keep you feeling better while you recover.
Stu
Early detection and treatment of Alzheimer's disease require the use of dependable and cost-effective screening technologies.
Researchers at Sweden's Karolinska Institutet have revealed that the level of tau, a protein that plays a vital role in the development of severe dementia, is
associated with a kind of sugar molecule in the blood.
The study, which is published in Alzheimer's & Dementia, can pave the way for a simple screening procedure able to predict onset ten years in advance.
"The role of glycans, structures made up of sugar molecules, is a relatively unexplored field in dementia research," says the study's first author Robin Zhou,
medical student and affiliated researcher at the Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet.
"We demonstrate in our study that blood levels of glycans are altered early during the development of the disease. This could mean that we'll be able to predict
the risk of Alzheimer's disease with only a blood test and a memory test."
In Alzheimer's disease, the neurons of the brain die, which is thought to be a result of the abnormal accumulation of the proteins amyloid beta and tau. Clinical
trials for Alzheimer's drugs show that treatment should commence early in the pathological process, before too many neurons have died, to reverse the process before
it is too late.
After receiving approval from the National Institute for Health and Care Excellence (NICE), the NHS is preparing to roll out a new combination treatment
for brain tumours in children and young people in England.
Dabrafenib with trametinib would be the first ever targeted treatment for children (aged 1-17) with gliomas that have a specific genetic mutation, the health
service said.
The treatment, which can be taken at home, has been found to slow the progression of the disease by over threefold compared to standard chemotherapy in children
with low-grade gliomas that have a BRAF V600E mutation. Clinical trials have shown that it causes fewer side-effects than chemotherapy.
NICE approved the combination treatment on Wednesday 24 April. It will be available on the NHS in the coming months.
The Labour Party's election manifesto, unveiled with a focus on bolstering community pharmacy services and enhancing localised healthcare, has sparked
responses from key pharmacy bodies across England.
A standout pledge within the manifesto is the commitment to establish a Community Pharmacist Prescribing Service, aimed at granting more pharmacists independent
prescribing rights.
This initiative is viewed as pivotal in recognising the clinical capabilities of pharmacists and their potential to alleviate pressures within primary care.
Additionally, Labour's plan advocates for broader healthcare access improvements, including enabling opticians to directly refer patients to specialist services
and expanding self-referral options where suitable.
The manifesto also introduces proposals to trial Neighbourhood Health Centres, designed to consolidate various healthcare services under one roof, such as family
doctors, district nurses, and mental health specialists.
A Canadian researcher involved in a study that uncovered a drug capable of significantly reducing the risk of breast cancer in high-risk, postmenopausal women calls the finding a "landmark" discovery. The American Society of Clinical Oncology announced that a massive international clinical trial has found the drug exemestane cuts the risk of cancer for such women by about two-thirds.